Overview

The Innotek antigen detection kit identifies influenza A virus, influenza B virus and Mycoplasma pneumoniae from a single specimen, supporting rapid differential diagnosis during respiratory infection seasons. As an in vitro diagnostic (IVD), the kit is subject to medical-device regulation that governs its performance claims, manufacturing and market access. This article outlines the regulatory pathways and quality expectations that apply to such multi-target antigen tests.

Regulatory Pathways for IVD Antigen Tests

IVDs are regulated separately from pharmaceuticals. In the European Union, antigen tests fall under the In Vitro Diagnostic Regulation (IVDR), requiring conformity assessment and CE marking with documented analytical and clinical performance. In the United States, such tests are typically cleared or authorized through the FDA, for example via 510(k) or Emergency Use Authorization routes depending on the context, with performance validated against a predicate or during a public-health emergency. In China, registration with the NMPA is required before legal marketing. Each pathway demands evidence of sensitivity, specificity and reproducibility appropriate to the intended use and setting. Manufacturers must also define the intended specimen type, such as nasopharyngeal swab or sputum, because performance can differ by sample and testing environment.

Quality Management and Market Access

Behind every authorized kit is a quality system. Manufacturers are expected to operate under ISO 13485, the international standard for medical-device quality management, covering design controls, supplier qualification, production and post-market surveillance. Lot-to-lot consistency, reference-material traceability and stability data support reliable performance across batches and storage conditions. Stability and shipping studies confirm the kit performs after transport and storage, evidence that purchasers should request before large-volume procurement. For buyers, confirming the specific regulatory status in the target market, CE mark, FDA authorization or NMPA registration, is the first step in compliant procurement, because a kit validated for one region is not automatically legal to market in another.

FAQ

Q: How are antigen tests regulated differently from drugs? A: They are medical devices governed by IVD rules such as EU IVDR, US FDA device pathways and NMPA registration, focused on analytical and clinical performance rather than pharmacological effect.

Q: What quality standard applies to IVD manufacturers? A: ISO 13485 is the recognized quality-management standard for medical-device makers, covering design, production and post-market controls.

Q: Does one regional approval cover global sales? A: No. CE marking, FDA authorization and NMPA registration are separate; a kit must hold the specific authorization required in each market it is sold in.